about
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinomaSuccinct guide to liver transplantation for medical studentsManagement of early hepatic artery occlusion after liver transplantation with failed rescueAbuse-related trauma forward medical care in a randomly sampled nationwide populationLongitudinal assessment of prognostic factors for patients with hepatorenal syndrome in a tertiary centerC1GALT1 promotes invasive phenotypes of hepatocellular carcinoma cells by modulating integrin β1 glycosylation and activityAdjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceManaging hepatitis B reactivation in renal transplant recipients: a 12-year review with emphasis on early detection and early use of lamivudine.Fibrin-Induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells as a mechanism of peritoneal fibrosis: effects of pentoxifyllineKnockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signalingManagement of hepatic angiomyolipoma.Nationwide longitudinal analysis of acute liver failure in taiwan.Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size.Post-transplant malignancy in liver transplantation: a single center experienceSurgical treatment of pancreatic serous cystadenoma: aggressive for operations but limited resections.Pediatric renal transplantation: results and prognostic factors.Quantification of hepatic steatosis: a comparison of the accuracy among multiple magnetic resonance techniques.The occurrence of primary hepatic adenoma in deceased donor renal transplant recipient.Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.Robotic major hepatectomy: Is there a learning curve?First Case Genotype 4 Hepatitis E Infection After a Liver Transplant.B cells and immunoglobulin in ABO-incompatible renal transplant patients receiving rituximab and double filtration plasmapheresis.RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.Evaluation of cyclosporine C2 levels in long-term stable renal allograft recipients.Successful Living-Donor Liver Transplant for Fulminant Hepatitis in a Heart Recipient.Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens.Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.Clinical course of de novo hepatitis B infection after pediatric liver transplantation.Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: report of five pediatric cases.Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression.Handport-assisted laparoscopic live-donor nephrectomy.Sirolimus antirejection therapy for renal transplantation with cyclosporine-based immunosuppression: case reports.Linear correlation between sirolimus and cyclosporine trough levels in renal transplant patients.Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age.Metabolic fate of extrahepatic arginine in liver after burn injury.Development of autoantibodies after pediatric liver transplantation.Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities.Unusual sonographic appearance of a gastrointestinal stromal tumor presenting as a large multilocular cystic mass.C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization.
P50
Q28073769-45CA9EC2-DE10-4F01-BDBB-4D72CE06C87BQ28075352-C0B4EA7A-9513-441D-8AE3-2A1E6F998BF2Q28084028-D2F3D232-6972-4605-BF50-92ABBCD7A791Q28596727-E07484B1-A1AF-417B-B45D-8DD0D1ABF93EQ33977165-020C3038-0538-4C7D-9C7C-2BAAB141522CQ33999174-6342560B-BE98-486F-B084-18D5C5FF9AB9Q34093919-D5E62B74-E355-40B0-A5FF-D9180C70436DQ34105964-BED4DF7A-D6A0-42D9-AEDE-A984F6C77138Q34427394-68FB83B2-E70C-4084-8324-2180C9A69908Q35742375-752D4EA9-FCB9-4FCB-9B0D-FD0CA4B9CFCFQ35751535-BF38BA3D-B637-4C31-8A87-141F0B728988Q36150763-BB2F1B82-B72D-4D49-B78F-1490395146B2Q36152525-E548F52E-4575-47E6-A3BB-6FE117347F0EQ36154140-9F5F97BE-9378-46CE-82C9-725F08D45C83Q37036127-04D234D3-E582-4869-9562-5590112259EBQ38092363-51A506A2-24CF-4B92-8CD5-BC114F2F715FQ38162260-22BC503A-99AC-455D-B477-286FE416DB39Q39228543-24BF354F-C3A0-4A41-8807-F9A1492F04FAQ39459644-7789C608-599B-4F99-99FA-0CAC997F0AD6Q40458410-E6677BD3-1F64-4E9E-91F8-27B7EF996BFAQ41084486-FC7B885D-FEA1-431A-8C37-8588348CEB71Q41118580-A3378668-061A-4FA8-B441-B5613E68D61AQ41576952-5C15C8E2-6220-424B-9682-D0045B76EBD6Q42169506-1BB2B1C9-573B-4B37-8EF1-EE3D4AA0B6BCQ42230152-9F429469-9B02-48C8-866C-6DF245715ECDQ42656832-BE9964AD-7ADF-4C8B-A11B-80B13E2F6772Q43204666-B96BB2B2-9059-469E-8C98-9564E4893A14Q43240442-0C0C7B40-3102-4B81-980F-E16E625D75FBQ43928776-094B5230-F816-4BC4-96CD-B75D9E2972B1Q43988028-56F3330A-4F6F-4DD7-B950-5AE3FB1DB2E7Q44171849-EDEE4004-5BFE-4CFD-B62E-79361DAF1B6FQ44319096-90709CDE-802D-4066-BA91-B6EF2A2A17E4Q44319158-93E8F3DE-2D9F-472B-ACCD-61409ADCD785Q44319172-CEF5CAA4-4E70-4A33-8C77-CE608758DF55Q44616328-099C89C7-15A5-40B7-88C9-32DAB60BA618Q44621486-7353916E-3ED4-409D-9CBA-107A5A4A8C77Q44715107-6A45EAD1-4347-4F00-A74E-0C2969E3ACFDQ44761898-1D50D743-850C-4DD7-B737-311AFB6F6982Q44853929-6E511AEC-CE3F-4B25-98F0-90E35E3DDCC5Q45158681-023121A0-0DE8-4FB8-8AA0-B39511768F52
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rey-heng Hu
@ast
Rey-heng Hu
@en
Rey-heng Hu
@es
Rey-heng Hu
@nl
Rey-heng Hu
@sl
type
label
Rey-heng Hu
@ast
Rey-heng Hu
@en
Rey-heng Hu
@es
Rey-heng Hu
@nl
Rey-heng Hu
@sl
prefLabel
Rey-heng Hu
@ast
Rey-heng Hu
@en
Rey-heng Hu
@es
Rey-heng Hu
@nl
Rey-heng Hu
@sl
P108
P106
P1153
7202640880
P31
P496
0000-0001-6709-031X